BACKGROUND: Intra-abdominal infections are common in young infants and lead to significant morbidity and mortality. Meropenem is a broad-spectrum antimicrobial with excellent activity against pathogens associated with intra-abdominal infections. The purpose of this study was to determine the safety and effectiveness of meropenem in young infants with suspected or complicated intra-abdominal infections. METHODS: Preterm and term infants <91 days of age with suspected or confirmed intra-abdominal infections hospitalized in 24 neonatal intensive care units were studied in an open-label, multiple-dose study. Adverse events and serious adverse events were collected through 3 and 30 days following the last meropenem dose, respectively. Effectiveness was assessed by 3 criteria: death, bacterial cultures, and presumptive clinical cure score. RESULTS: Of 200 subjects enrolled in the study, 99 (50%) experienced an adverse event, and 34 (17%) had serious adverse events; no adverse events were probably or definitely related to meropenem. The most commonly reported adverse events were sepsis (6%), seizures (5%), elevated conjugated bilirubin (5%), and hypokalemia (5%). Only 2 of the serious adverse events were determined to be possibly related to meropenem (isolated ileal perforation and an episode of fungal sepsis). Effectiveness was evaluable in 192 (96%) subjects, and overall treatment success was 84%. CONCLUSIONS: Meropenem was well tolerated in this cohort of critically ill infants, and the majority of infants treated with meropenem met the definition of therapeutic success. CLINICAL TRIALS REGISTRATION: NCT00621192.
BACKGROUND:Intra-abdominal infections are common in young infants and lead to significant morbidity and mortality. Meropenem is a broad-spectrum antimicrobial with excellent activity against pathogens associated with intra-abdominal infections. The purpose of this study was to determine the safety and effectiveness of meropenem in young infants with suspected or complicated intra-abdominal infections. METHODS: Preterm and term infants <91 days of age with suspected or confirmed intra-abdominal infections hospitalized in 24 neonatal intensive care units were studied in an open-label, multiple-dose study. Adverse events and serious adverse events were collected through 3 and 30 days following the last meropenem dose, respectively. Effectiveness was assessed by 3 criteria: death, bacterial cultures, and presumptive clinical cure score. RESULTS: Of 200 subjects enrolled in the study, 99 (50%) experienced an adverse event, and 34 (17%) had serious adverse events; no adverse events were probably or definitely related to meropenem. The most commonly reported adverse events were sepsis (6%), seizures (5%), elevated conjugated bilirubin (5%), and hypokalemia (5%). Only 2 of the serious adverse events were determined to be possibly related to meropenem (isolated ileal perforation and an episode of fungal sepsis). Effectiveness was evaluable in 192 (96%) subjects, and overall treatment success was 84%. CONCLUSIONS:Meropenem was well tolerated in this cohort of critically ill infants, and the majority of infants treated with meropenem met the definition of therapeutic success. CLINICAL TRIALS REGISTRATION: NCT00621192.
Authors: B R Vohr; L L Wright; A M Dusick; L Mele; J Verter; J J Steichen; N P Simon; D C Wilson; S Broyles; C R Bauer; V Delaney-Black; K A Yolton; B E Fleisher; L A Papile; M D Kaplan Journal: Pediatrics Date: 2000-06 Impact factor: 7.124
Authors: A Kubota; T Yonekura; M Hoki; H Oyanagi; H Kawahara; M Yagi; K Imura; Y Iiboshi; K Wasa; S Kamata; A Okada Journal: J Pediatr Surg Date: 2000-07 Impact factor: 2.545
Authors: D K Stevenson; L L Wright; J A Lemons; W Oh; S B Korones; L A Papile; C R Bauer; B J Stoll; J E Tyson; S Shankaran; A A Fanaroff; E F Donovan; R A Ehrenkranz; J Verter Journal: Am J Obstet Gynecol Date: 1998-12 Impact factor: 8.661
Authors: Laura E Miller; Chris DeRienzo; P Brian Smith; Carl Bose; Reese H Clark; C Michael Cotten; Daniel K Benjamin; Chi D Hornik; Rachel G Greenberg Journal: J Perinatol Date: 2020-10-08 Impact factor: 2.521
Authors: Constanza Chacón-González; Daniel Rivera-Salgado; Helena Brenes-Chacón; Gabriela Naranjo-Zuñiga; María L Ávila-Aguero Journal: Cureus Date: 2021-06-21
Authors: Christoph P Hornik; Daniel K Benjamin; P Brian Smith; Michael J Pencina; Adriana H Tremoulet; Edmund V Capparelli; Jessica E Ericson; Reese H Clark; Michael Cohen-Wolkowiez Journal: J Pediatr Date: 2016-08-10 Impact factor: 6.314